Cara Therapeutics, Inc.Cara Therapeutics, Inc.Cara Therapeutics, Inc.

Cara Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪36.13 M‬USD
‪−118.51 M‬USD
‪20.97 M‬USD
‪46.46 M‬
Beta (1Y)

About Cara Therapeutics, Inc.

Christopher A. Posner
Employees (FY)
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Revenue to profit conversion
Debt level and coverage

See all ideas 

Summarizing what the indicators are suggesting.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of CARA is 0.6610 USD — it has decreased by 4.20% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cara Therapeutics, Inc. stocks are traded under the ticker CARA.
Cara Therapeutics, Inc. is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
CARA stock is 7.05% volatile and has beta coefficient of 2.67. Check out the list of the most volatile stocks — is Cara Therapeutics, Inc. there?
One year price forecast for Cara Therapeutics, Inc. has a max estimate of 10.0000 USD and a min estimate of 1.0000 USD.
CARA earnings for the last quarter are −0.52 USD per share, whereas the estimation was −0.52 USD resulting in a 0% surprise. The estimated earnings for the next quarter are −0.45 USD per share. See more details about Cara Therapeutics, Inc. earnings.
Cara Therapeutics, Inc. revenue for the last quarter amounts to ‪4.90 M‬ USD despite the estimated figure of ‪9.95 M‬ USD. In the next quarter revenue is expected to reach ‪9.42 M‬ USD.
Yes, you can track Cara Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
CARA stock has fallen by 18.40% compared to the previous week, the month change is a 24.02% fall, over the last year Cara Therapeutics, Inc. has showed a 84.22% decrease.
CARA net income for the last quarter is ‪−32.34 M‬ USD, while the quarter before that showed ‪−28.03 M‬ USD of net income which accounts for −15.36% change. Track more Cara Therapeutics, Inc. financial stats to get the full picture.
Today Cara Therapeutics, Inc. has the market capitalization of ‪36.13 M‬, it has decreased by 10.22% over the last week.
No, CARA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CARA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cara Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
CARA reached its all-time high on Apr 9, 2021 with the price of 29.6473 USD, and its all-time low was 0.5000 USD and was reached on Jan 25, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 22, 2024, the company has 55.00 employees. See our rating of the largest employees — is Cara Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cara Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cara Therapeutics, Inc. stock shows the sell signal. See more of Cara Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Cara Therapeutics, Inc. future price: according to them, CARA price has a max estimate of 10.00 USD and a min estimate of 1.00 USD. Read a more detailed Cara Therapeutics, Inc. forecast: see what analysts think of Cara Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cara Therapeutics, Inc. EBITDA is ‪−120.02 M‬ USD, and current EBITDA margin is −578.20%. See more stats in Cara Therapeutics, Inc. financial statements.